eBook | VHH antibody engineering: a new tool for the therapeutic development pipeline
Antibody discovery is at the core of therapeutics research. VHH antibodies, also known as single-domain antibodies, offer a smaller, engineerable alternative to traditional antibodies, overcoming many of their limitations.
In this eBook, in partnership with Abcore (CA, USA), a Fortis Life SciencesTM (MA, USA) company, we highlight how VHH antibodies are being developed and harnessed for therapeutic purposes, delving into the scaffolds used to generate and discover them and examples of their real-world applications against disease.
Download nowContents
- Introduction
- Editorial: IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents
- Poster: Nanomolar VHH binders of PD-L1 and other therapeutic targets from the AbNanoTM VHH Naive Library
- Research Article: Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery of antibodies, which recognized native receptor
- Original Article: Development and utilization of VHH antibodies derived from Camelus Dromedarius against foot-and-mouth disease virus
- White Paper: VHH antibodies: novel engineering strategies beget diverse applications
This eBook was supported by Abcore.
